OBJECTIVES: To test whether structured physical activity (PA) is associated with a greater reduction in major mobility disability (MMD) in older persons with metabolic syndrome (MetS) than in those without. DESIGN: Data from the Lifestyle Interventions and Independence for Elders (LIFE) Study, a multicenter randomized trial of 1,635 persons with assessments every 6 months (average 2.7 years). SETTING: Eight U.S. centers. PARTICIPANTS: Sedentary men and women aged 70 to 89 with functional limitations (N = 1,535); 100 participants were excluded because of missing MetS data. INTERVENTION: Participants were randomized to a moderate-intensity PA program (n = 766) or a health education program (n = 769). MEASUREMENTS: MetS was defined according to the 2009 multiagency harmonized criteria. Outcomes included incident MMD (loss of ability to walk 400 m) and persistent MMD (two consecutive MMD diagnoses or one MMD diagnosis followed by death). RESULTS: Seven hundred sixty-three (49.7%) participants met criteria for MetS. PA reduced incident MMD more than health education did in participants with MetS (hazard ratio (HR) = 0.72, 95% confidence interval (CI) = 0.57-0.91, P = .007) but not in those without MetS (HR = 0.96, 95% CI = 0.73-1.25, P = .75); the test for statistical interaction was not significant (P = .13). PA reduced the risk of persistent MMD in participants with MetS (HR = 0.57, 95% CI = 0.41-0.79, P < .001) but not in those without MetS (HR = 0.97, 95% CI = 0.67-1.41, P = .87). The test for statistical interaction was significant (P = .04). CONCLUSION: Moderate-intensity PA substantially reduces the risk of persistent MMD in older persons with functional limitations with MetS but not in those without MetS. Comparable results were observed for incident MMD. The LIFE PA program may be an effective strategy for reducing mobility disability in vulnerable older persons with MetS.
M
etabolic syndrome (MetS) 1 has been identified in approximately 50% of older adults 2 in the United States. Sedentary behavior is a risk factor for MetS, 3 whereas physical activity (PA) may slow progression toward MetS independent of multiple confounding factors. 4 Previous studies have documented an association between MetS and subsequent decline in multiple measures of functional status, including mobility. 5, 6 These adverse effects are highly predictive of disability, hospitalization, nursing home admission, and mortality. 7 Thus, the relationship between MetS and PA, individually and together, and subsequent mobility disability are of clinical and public health importance.
Structured PA is effective in preventing mobility disability in older adults with functional limitations. 8 Prior studies indicate that obesity, a well-documented precursor of MetS, may modify the mobility-preserving effect of PA, although the direction of the association is unclear; whereas some studies found no mobility benefit 9 or an attenuated benefit 10 of PA in obese individuals, others found a greater benefit, 11, 12 suggesting a potential differential effect of PA on mobility disability according to metabolic status. The objective of the current study was to determine whether baseline MetS modifies the beneficial effect of a structured PA intervention on mobility disability in a sample of vulnerable older adults with functional limitations.
METHODS

Study Design and Participants
The Lifestyle Interventions and Independence for Elders (LIFE) Study was a Phase 3, single-blind, multicenter, parallel randomized-controlled trial that compared the effects of a moderate-intensity PA program with those of a health education (HE) program on incidence of major mobility disability (MMD; defined as inability to walk 400 m in <15 minutes) in 1,635 adults aged 70 to 89 with functional limitations. The study design, inclusion and exclusion criteria, randomization procedure ( Figure S1 ), and intervention protocol have been described in detail elsewhere. 8, 13 Briefly, potential participants were considered eligible if they were sedentary (<20 min/wk of structured PA in the past month and reporting ≤125 min/wk of moderate PA), 14 had functional limitations (Short Physical Performance Battery (SPPB) score ≤9), 7 and were able to walk 400 m in less than 15 minutes unassisted without sitting or leaning. The exclusion criteria were designed to identify persons who were likely to be incapable of fully participating in the interventions because of comorbid conditions or cognitive impairment and those for whom PA would be unsafe. 8 This article presents results for a secondary post hoc analysis that was not prespecified in the study protocol but was prespecified in a proposal that the LIFE Publications and Presentations Committee approved before initiation.
Analytical Sample
Of 1,635 LIFE participants, 818 were randomized to PA and 817 to HE. The present study excluded 100 participants (52 from PA, 48 from HE) for whom baseline MetS status could not be determined because of missing data, resulting in an analytical sample of 1,535 participants.
Intervention and Follow-Up Schedule
The two interventions, including adherence, have been described in detail elsewhere. 8, 13 Briefly, the PA intervention required attendance at two center-based visits per week and home-based activities three to four times per week. The program included walking, with a goal of 30 minutes per session of moderate-intensity walking or 150 minutes per week, and flexibility, strength, and balance training. The PA group attended an average of 63% of the scheduled sessions (median 71%, interquartile range (IQR) 50-83%).
The HE program involved weekly workshops focused on successful aging topics for the first 26 weeks and monthly workshops thereafter. The HE group also participated in a 5-to 10-minute instructor-led program of stretching exercises. HE participants attended an average of 73% of the scheduled sessions (median 82%, IQR 63-90%).
Measures
Major Mobility Disability
The outcomes were incident and persistent MMD. MMD was defined as the inability to complete a usual-pace 400-m walk without sitting or the help of another person or walker. (Use of a straight cane was permitted.) Participants were assessed every 6 months for up to 42 months. As previously described, 8 for participants who were unable to come to the clinic, MMD definition was based on objective inability to walk 4 m in less than 10 seconds or documented inability to walk across a room. Deaths were ascertained through regular surveillance. Incident MMD was defined as newly developed MMD. Because newly disabled individuals may recover, 15 severe, nonreversible MMD (two consecutive MMD diagnoses or one MMD diagnosis followed by death) was also determined. The number needed to treat for the main outcome (MMD) in the LIFE Study was 51 for an intervention durations of 1 year, 26 for 2 years, and 17 for 3 years.
Metabolic Syndrome
MetS was measured at baseline using the harmonized criteria from the 2009 Joint Interim Statement 1 as the presence of three or more of the following components: abdominal obesity (waist circumference ≥102 cm in men, ≥88 cm in women), low high-density lipoprotein cholesterol (<40 mg/ dL in men, <50 mg/dL for women, or drug treatment), high triglycerides (≥150 mg/dL or drug treatment), hypertension (systolic blood pressure ≥130 mmHg, diastolic blood pressure ≥85 mmHg, or antihypertensive drug treatment with a history of physician-diagnosed hypertension), high fasting plasma glucose (≥100 mg/dL or drug treatment for diabetes mellitus). MetS was coded as absent or present.
Other Measures
Details about the main baseline assessments (summarized in Table 1 ), including sociodemographic and health status information, have been previously described. 8, 16 Statistical Analysis Baseline characteristics were summarized according to MetS status and intervention group using means and Missing values account for the small discrepancies between total n (in each column) and the values listed under each descriptive characteristic.
a MetS defined as the presence of three or more of: abdominal obesity (waist circumference ≥102 cm in men, ≥ 88 cm in women), low high-density lipoprotein cholesterol (HDL-C) (<40 mg/dL for men, <50 mg/dL for women or drug treatment), high triglycerides (≥150 mg/dL or drug treatment), hypertension (systolic blood pressure ≥130 mmHg, diastolic blood pressure ≥85 mmHg, or antihypertensive drug treatment with a history of physician-diagnosed hypertension), and high fasting plasma glucose (≥100 mg/dL or drug treatment for diabetes mellitus).
b Participant report of physician-diagnosed angina pectoris or myocardial infarction, congestive heart failure, stroke, cancer, or lung disease (absent/present for all five conditions), and peripheral arterial disease (ankle-brachial index <0.9). 17 were analyzed using mixed-effects analysis of covariance models for repeatedly measured outcomes with an unstructured parameterization for longitudinal covariance.
For primary analyses, incident and persistent MMD were summarized according to intervention group and MetS status. Cox regression models were used to assess the potential modifying effect of MetS status on the effectiveness of the PA intervention in preventing incident and persistent MMD. Discrete time to failure was measured from date of randomization. The proportion of event-free participants over time was calculated using Kaplan-Meier estimates. Participants who remained event free until death or the last follow-up visit were censored at their last available assessment. All models included the main effects of MetS status and intervention group and their interaction. Study design variables (sex, clinical site) were used as stratification factors in all models. Finally, because of earlier reports showing associations between MetS severity and mobility disability, 6 supplementary analyses were conducted with MetS as an ordinal variable (range 0-5), indicating the number of MetS components identified in each participant.
All analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC) and P < .05 was considered statistically significant.
RESULTS
Participant demographic and health characteristics are summarized in Table 1 ; 763 (49.7%) participants had three or more MetS criteria, thus fulfilling the requirements for MetS, and 772 (50.3%) had two or fewer criteria. Baseline characteristics were similar between PA and HE participants within each MetS subgroup.
Intervention Adherence and Attrition
PA participants in the MetS and non-MetS subgroups attended an average of approximately 63% of the scheduled sessions; HE participants attended an average of 73% (MetS subgroup) and 74% (non-MetS subgroup) of the sessions. Follow-up and attrition indicators were similar in the MetS intervention subgroups. Differences in accelerometer-based minutes of PA between the PA and HE groups within each MetS group were maintained over time (Table S1 ).
Outcomes
One hundred twenty-nine (33.4%) MetS/PA participants and 158 (41.9%) MetS/HE participants experienced incident MMD; 103 (27.1%) non-MetS/PA participants and 112 (28.6%) non-MetS/HE participants experienced newonset MMD. Persistent MMD was observed in 59 (15.3%) MetS/PA participants and 95 (25.2%) MetS/HE participants; persistent MMD was observed in 54 (14.2%) non-MetS/PA participants and 57 (14.4%) non-MetS/HE participants.
Kaplan-Meier curves for incident and persistent MMD are provided in Figures 1 and 2 , respectively. The PA intervention was beneficial in reducing incident MMD in participants with MetS (HR = 0.72, 95% CI = 0.57-0.91) but not in those without MetS (HR = 0.96, 95% CI = 0.73-1.25), although the test for statistical interaction was not significant (P = .13) (Figure 1 ). In contrast, the test for statistical interaction was significant for persistent MMD (P = .04) (Figure 2 ). The risk of persistent MMD in participants with MetS was lower in the PA than the HE group (HR = 0.57, 95% CI = 0.41-0.79) but not in those without MetS (HR = 0.97, 95% CI = 0.67-1.41].
Supplementary analyses with MetS as an ordinal variable showed a differential treatment effect of the PA intervention (vs HE) according to MetS severity (increasing number of MetS criteria) for persistent MMD (P for interaction = .03), but not for incident MMD (P for interaction = .23). For both outcomes, the effect of the PA intervention (relative to HE) was stronger at higher MetS counts than lower MetS counts, with each unit increase in MetS criteria count associated with a 19% corresponding decrease in HR for persistent MMD and an 8% corresponding decrease for incident MMD.
DISCUSSION
In this analysis of data from a large clinical trial, structured PA reduced the risk of persistent MMD substantially more than did HE in older persons with MetS but not in those without MetS. The results were similar for incident MMD, although the difference in risk reduction between the MetS subgroups was not statistically significant. The large reduction in major mobility disability in the MetS group is of particular clinical and public health importance given the high prevalence of MetS, the health and economic consequences of losing independent mobility, and the scarcity of proven interventions to avert mobility disability in this vulnerable older population.
Consistent with prior estimates, 2 MetS was highly prevalent (~50%) in this sample of functionally impaired older persons. The supplementary results, with metabolic dysfunction ranging from 0 (none of criteria present) to 5 (all criteria present), were consistent with those from the primary analyses; a stronger treatment effect was observed at higher number of MetS components for persistent and incident MMD, although the formal test for statistical interaction was not significant for the latter.
Although the number of persistent and incident MMD cases was smaller in the non-MetS than the MetS groups, the intervention had a larger benefit in the MetS group for both mobility outcomes. The finding of a greater benefit in reducing persistent MMD (43% reduction in risk) than incident MMD (28% reduction) suggests that PA facilitates recovery in older persons with MetS who have lost independent mobility. The difference between the number of incident and persistent events in MetS participants (Figures 1 and 2) indicates that 70 of 129 (54.3%) MetS/PA participants recovered their mobility after a first MMD event, compared with 95 of 158 (39.8%) MetS/HE participants. In contrast, for non-MetS participants, although a relatively large number of incident MMD cases did not become persistent cases, it appears that the likelihood of recovery from newly developed mobility disability was similar in PA and HE participants. These findings call for further investigation to identify factors that promote recovery from newly developed mobility disability in older persons without MetS.
Despite the substantial benefit of PA in preventing a first episode of MMD in the MetS subgroup, the difference in risk reduction between the MetS and non-MetS subgroups did not reach statistical significance in the primary or supplementary analyses. The LIFE Study was powered to detect clinically meaningful reductions in MMD according to intervention group for all participants 8 but not within specific subgroups. Because the analyses were not prespecified in the original study protocol, and 100 participants were omitted because of missing baseline MetS data, the possibility cannot be excluded that a larger sample or longer follow-up would have resulted in statistically significant subgroup differences.
Several possible explanations for the observed benefit of PA in reducing mobility disability in participants with but not without MetS merit comment. First, the results may reflect differences in the biological processes contributing to mobility disability in the two metabolic groups. The mechanisms responsible for mobility impairments in individuals with MetS have been extensively investigated. MetS and some of its components (in particular the combination of abdominal obesity and hyperglycemia) 6 have been linked to muscle deficiency, 18, 19 chronic inflammatory and oxidative stress processes, 20, 21 low cardiorespiratory fitness, 22 and biomechanical leg stress. 19 In turn, prior observational and intervention studies have demonstrated robust beneficial effects of PA on these processes. [23] [24] [25] In contrast, the current study findings suggest that mobility disability in persons without MetS may result from processes that are not responsive to moderate PA, such as central and peripheral neuroaging, 26, 27 age-related sensory impairments, 28 and loss of proprioception. 29 It is unclear whether the contribution of these factors to mobility disability differs between persons with and without MetS. Because PA may provide other health benefits to persons without MetS, these findings should not be interpreted to mean that persons without MetS should not engage in PA. Additional work is needed to elucidate the mechanisms underlying mobility disability in individuals without MetS as a first step toward identifying mobilitypreserving interventions for this group. Comparison of effect of physical activity (PA) intervention with that of health education (HE) on incident major mobility disability (MMD), according to metabolic syndrome (MetS) status. The graph for incident major mobility disability was truncated at 3.5 years; the non-MetS/HE subgroup had one additional MMD event and the MetS/HE subgroup had two additional MMD events between 3.5 and 3.6 years of follow-up. Number of events represents cumulative events, and adjusted hazard ratios (HRs) and P-values are from proportional hazards regression models adjusted for sex and clinical site, as described in the Statistical Analysis section.
It is unlikely that differences in adherence to the PA intervention can explain the differential benefit of PA between the MetS and non-MetS subgroups because the percentage of sessions attended within each intervention arm were similar between the two subgroups (Table 1) , and the difference in objectively assessed minutes of PA between PA and HE participants in the MetS and nonMetS groups was maintained over time (Appendix S1).
To the knowledge of the authors, this is the first study to assess the effectiveness of a structured PA intervention in individuals with and without MetS at high risk of mobility disability. This study has important strengths, including an objectively measured outcome of high clinical relevance in older adults; 30 assessment of MetS based on updated harmonized criteria, 1 allowing for comparison across studies; high retention and intervention adherence rates; and a larger sample and longer follow-up than other randomized trials of PA in older populations. 8 In addition to being a post hoc analysis and not being powered to detect subgroup differences, this study had at least three other limitations. First, information on the duration of MetS, which may be associated with risk of incident and persistent mobility disability and likelihood of benefit from the PA intervention, was not available. Second, the 2.7 years of average follow-up is short relative to the 9-year life expectancy of the LIFE cohort. 8 Third, because the target population included sedentary older persons with functional limitations, the results may not be generalizable to younger or more functionally intact persons.
In conclusion, structured moderate-intensity PA substantially reduces the risk of persistent major mobility disability in sedentary, functionally impaired older adults with MetS but not in those without MetS. Although not statistically significant, comparable results were observed for incident major mobility disability. These findings, coupled with the demonstrated safety of the PA program, support further evaluation of this program as a cost-effective strategy for reducing mobility disability in vulnerable older persons with MetS. Additional research is needed to clarify the mechanisms underlying mobility disability in metabolically healthy older persons and to identify feasible and effective interventions aimed at reducing the risk of disability in this group.
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